bpi labs tirzepatide is challenging the patent. This is a second challenge as Empower pharmacy was already challenging the patent. BPI includes additional imformation including a previous patent application showing GLP-1/GIP as Shop - MedSpa

Further studies are needed to clarify optimal dose and delivery forms and one mandatory target should be the identification of sub-groups of individuals most likely to respond to particular supplements, nutrients or foods

Chemical peels and strong cosmetic products should not be used in the area where the treatment will be performed for a few days after the treatment

While GLP-1s are effective at suppressing appetite and reducing food intake in the short term, emerging research raises concerns about weight cyclingthe repeated loss and regain of weightwhich is both common and biologically driven after discontinuation

This is a critical technical distinction

Rossi G et al